Dr. Paul Sax recaps the astonishing success and now failure of Paxlovid in
HIV and ID Observations.
Data from a study recently published in the New England Journal of Medicine further confirm that treating COVID-19 with nirmatrelvir with ritonavir has many limitations. But we shouldn't completely abandon Paxlovid for outpatient use, especially for people at high risk for adverse outcomes, says Dr. Paul Sax in the latest HIV and ID Observations.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.